The role of inflammasomes in atherosclerosis and stroke pathogenesis

Deepaneeta Sarmah, Aishika Datta, Swapnil Raut, Ankan Sarkar, Birva Shah, Mariya Bohra, Upasna Singh, Priya Jagtap, Falguni Baidya, Kiran Kalia, Xin Wang, Kunjan R. Dave, Dileep R Yavagal, Pallab Bhattacharya

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Inflammation is a devastating outcome of cerebrovascular diseases (CVD), namely stroke and athero-sclerosis. Numerous studies over the decade have shown that inflammasomes play a role in mediating inflammatory reactions post cellular injury occurring after a stroke or a rupture of an atherosclerotic plaque. In view of this, targeting these inflammatory pathways using different pharmacological therapies may improve outcomes in patients with CVD. Here, we review the mechanisms by which inflammasomes drive the pathogenesis of stroke and atherosclerosis. Also, discussed here are the possible treatment strategies available for inhibiting inflammasomes or their up-stream/down-stream mediators.

Original languageEnglish (US)
Pages (from-to)4234-4245
Number of pages12
JournalCurrent pharmaceutical design
Volume26
Issue number34
DOIs
StatePublished - 2020

Keywords

  • Atherosclerosis
  • Inflammasomes
  • Inflammation
  • NLRP
  • Stroke
  • Therapies

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'The role of inflammasomes in atherosclerosis and stroke pathogenesis'. Together they form a unique fingerprint.

  • Cite this

    Sarmah, D., Datta, A., Raut, S., Sarkar, A., Shah, B., Bohra, M., Singh, U., Jagtap, P., Baidya, F., Kalia, K., Wang, X., Dave, K. R., Yavagal, D. R., & Bhattacharya, P. (2020). The role of inflammasomes in atherosclerosis and stroke pathogenesis. Current pharmaceutical design, 26(34), 4234-4245. https://doi.org/10.2174/1381612826666200427084949